- Home
- ANSS vs ONC Comparison
ANSS vs ONC Comparison
Compare ANSS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSS
- ONC
- Stock Information
- Founded
- ANSS 1970
- ONC 2010
- Country
- ANSS United States
- ONC Switzerland
- Employees
- ANSS N/A
- ONC N/A
- Industry
- ANSS Computer Software: Prepackaged Software
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- ANSS Technology
- ONC Health Care
- Exchange
- ANSS Nasdaq
- ONC Nasdaq
- Market Cap
- ANSS 30.4B
- ONC 26.9B
- IPO Year
- ANSS 1996
- ONC N/A
- Fundamental
- Price
- ANSS $334.96
- ONC $247.08
- Analyst Decision
- ANSS Hold
- ONC Strong Buy
- Analyst Count
- ANSS 3
- ONC 7
- Target Price
- ANSS $352.50
- ONC $326.43
- AVG Volume (30 Days)
- ANSS 846.6K
- ONC 314.8K
- Earning Date
- ANSS 07-30-2025
- ONC 08-06-2025
- Dividend Yield
- ANSS N/A
- ONC N/A
- EPS Growth
- ANSS 35.35
- ONC N/A
- EPS
- ANSS 6.74
- ONC N/A
- Revenue
- ANSS $2,583,095,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- ANSS $11.68
- ONC $869.15
- Revenue Next Year
- ANSS $9.99
- ONC $19.07
- P/E Ratio
- ANSS $49.92
- ONC N/A
- Revenue Growth
- ANSS 15.98
- ONC 51.16
- 52 Week Low
- ANSS $275.06
- ONC $141.31
- 52 Week High
- ANSS $363.03
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- ANSS 47.66
- ONC N/A
- Support Level
- ANSS $335.69
- ONC N/A
- Resistance Level
- ANSS $349.00
- ONC N/A
- Average True Range (ATR)
- ANSS 4.75
- ONC 0.00
- MACD
- ANSS -1.21
- ONC 0.00
- Stochastic Oscillator
- ANSS 40.23
- ONC 0.00
About ANSS ANSYS Inc.
Ansys is an engineering software company that provides simulation capabilities for structural, fluids, semiconductor power, embedded software, optical, and electromagnetic properties. Ansys employs over 4,000 people and serves over 50,000 customers globally.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.